Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Acinetobacter Infections Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Acinetobacter Infections Overview | 13 | 1 |
| Pipeline Products for Acinetobacter Infections Comparative Analysis | 14 | 1 |
| Acinetobacter Infections Therapeutics under Development by Companies | 15 | 2 |
| Acinetobacter Infections Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Acinetobacter Infections Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Acinetobacter Infections Products under Development by Companies | 21 | 3 |
| Acinetobacter Infections Products under Investigation by Universities/Institutes | 24 | 1 |
| Acinetobacter Infections Companies Involved in Therapeutics Development | 25 | 28 |
| Achaogen Inc. | 25 | 1 |
| Adenium Biotech ApS | 26 | 1 |
| Aridis Pharmaceuticals LLC | 27 | 1 |
| AstraZeneca Plc | 28 | 1 |
| AvidBiotics Corp. | 29 | 1 |
| Cellceutix Corporation | 30 | 1 |
| Emergent BioSolutions Inc. | 31 | 1 |
| Entasis Therapeutics Inc | 32 | 1 |
| Evaxion Biotech ApS | 33 | 1 |
| F. Hoffmann-La Roche Ltd. | 34 | 1 |
| FOB Synthesis, Inc. | 35 | 1 |
| Hsiri Therapeutics, LLC | 36 | 1 |
| LegoChem Biosciences, Inc | 37 | 1 |
| Melinta Therapeutics, Inc | 38 | 1 |
| MicuRx Pharmaceuticals, Inc. | 39 | 1 |
| Nosopharm SAS | 40 | 1 |
| Novabiotics Limited | 41 | 1 |
| Omnia Molecular Ltd. | 42 | 1 |
| Peptilogics, Inc. | 43 | 1 |
| Pfizer Inc. | 44 | 1 |
| Sarepta Therapeutics, Inc. | 45 | 1 |
| Sealife PHARMA GMBH | 46 | 1 |
| Shionogi &Co., Ltd. | 47 | 1 |
| Techulon, Inc. | 48 | 1 |
| Tetraphase Pharmaceuticals Inc. | 49 | 1 |
| Varinel, Inc. | 50 | 1 |
| Vaxdyn, S.L. | 51 | 1 |
| Xellia Pharmaceuticals ApS | 52 | 1 |
| Acinetobacter Infections Therapeutics Assessment | 53 | 9 |
| Assessment by Monotherapy Products | 53 | 1 |
| Assessment by Target | 54 | 2 |
| Assessment by Mechanism of Action | 56 | 2 |
| Assessment by Route of Administration | 58 | 2 |
| Assessment by Molecule Type | 60 | 2 |
| Drug Profiles | 62 | 64 |
| A-3APO Drug Profile | 62 | 2 |
| AA-139 Drug Profile | 64 | 1 |
| ACHN-975 Prodrug Drug Profile | 65 | 1 |
| Acinetobacter vaccine Drug Profile | 66 | 1 |
| Antisense Oligonucleotide for Acinetobacter baumannii Infections Drug Profile | 67 | 1 |
| Antisense Oligonucleotide for Acinetobacter baumannii Infections Drug Profile | 68 | 1 |
| AR-401 Drug Profile | 69 | 1 |
| AvR2-V10 Drug Profile | 70 | 2 |
| CA-824 Drug Profile | 72 | 1 |
| ETX-2514 Drug Profile | 73 | 1 |
| EV-035 Drug Profile | 74 | 2 |
| Fab-001 Drug Profile | 76 | 1 |
| FSI-1671 Drug Profile | 77 | 1 |
| FSI-1686 Drug Profile | 78 | 1 |
| GN-4474 Drug Profile | 79 | 1 |
| HT-06 Drug Profile | 80 | 1 |
| HT-07 Drug Profile | 81 | 1 |
| HT-10 Drug Profile | 82 | 1 |
| LCB-010200 Drug Profile | 83 | 1 |
| LCB-100200 Drug Profile | 84 | 1 |
| MDN-0057 Drug Profile | 85 | 2 |
| Monoclonal Antibodies for Gram-Negative Bacterial Infections Drug Profile | 87 | 1 |
| MRX-V Drug Profile | 88 | 1 |
| NOSO-95179 Drug Profile | 89 | 1 |
| NP-432 Drug Profile | 90 | 1 |
| OM-011818 Drug Profile | 91 | 1 |
| Peptides for Infectious Diseases Drug Profile | 92 | 1 |
| PMX-100 Drug Profile | 93 | 1 |
| PMX-1091 Drug Profile | 94 | 1 |
| PMX-1142 Drug Profile | 95 | 1 |
| PMX-229 Drug Profile | 96 | 1 |
| PMX-633 Drug Profile | 97 | 1 |
| pneumonia vaccine Drug Profile | 98 | 1 |
| RX-05 Drug Profile | 99 | 1 |
| RXP-873 Drug Profile | 100 | 1 |
| S-649266 Drug Profile | 101 | 2 |
| SLP-0901 Drug Profile | 103 | 1 |
| SLP-0905 Drug Profile | 104 | 1 |
| Small Molecule for Acinetobacter baumannii Infections Drug Profile | 105 | 1 |
| Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections Drug Profile | 106 | 1 |
| Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections Drug Profile | 107 | 1 |
| Small Molecules for Acinetobacter baumannii Infection Drug Profile | 108 | 1 |
| Small Molecules for Acinetobacter Infections Drug Profile | 109 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 110 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 111 | 1 |
| Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile | 112 | 1 |
| Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections Drug Profile | 113 | 1 |
| Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections Drug Profile | 114 | 1 |
| Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections Drug Profile | 115 | 1 |
| SPR-741 Drug Profile | 116 | 1 |
| Synthetic Peptide for Gram-Negative Bacterial Infections Drug Profile | 117 | 1 |
| TP-6076 Drug Profile | 118 | 1 |
| VAR-10100 Drug Profile | 119 | 1 |
| VXD-001 Drug Profile | 120 | 1 |
| VXD-003 Drug Profile | 121 | 1 |
| XEL-1001 Drug Profile | 122 | 1 |
| XEL-1002 Drug Profile | 123 | 1 |
| XEL-1003 Drug Profile | 124 | 1 |
| XEL-1007 Drug Profile | 125 | 1 |
| Acinetobacter Infections Dormant Projects | 126 | 2 |
| Acinetobacter Infections Product Development Milestones | 128 | 1 |
| Featured News &Press Releases | 128 | 1 |
| Sep 01, 2014: AA139, Adenium Clinical Product Candidate Against Multi-Drug Resistant Gram-Negative Bacteria to be Presented at ICAAC in Washington | 128 | 1 |
| Appendix | 129 | 2 |
| Methodology | 129 | 1 |
| Coverage | 129 | 1 |
| Secondary Research | 129 | 1 |
| Primary Research | 129 | 1 |
| Expert Panel Validation | 129 | 1 |
| Contact Us | 129 | 1 |
| Disclaimer | 130 | 1 |